Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01917279
Other study ID # ML28898
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 2013
Est. completion date July 2021

Study information

Verified date July 2020
Source Chinese Academy of Medical Sciences
Contact Binghe Xu, MD, PhD
Phone +86-10-87788826
Email xubinghe@medmail.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is a phase III trial to explore the efficacy and safety of metronomic chemotherapy with Capecitabine versus intermittent Capecitabine as maintenance therapy following first-line Capecitabine plus Docetaxel chemotherapy in treatment of HER2-negative metastatic breast cancer(mBC).


Recruitment information / eligibility

Status Recruiting
Enrollment 280
Est. completion date July 2021
Est. primary completion date July 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Signed informed consent obtained prior to initiation of any study-specific procedures or treatment as confirmation of the patient's awareness and willingness to comply with the study requirements.

- Female patients aged = 18 years.

- Histologically confirmed and documented HER2-negative metastatic breast cancer.

- Previously untreated first-line chemotherapy.

- Patients with at least one measurable lesion according to RECIST criteria at study entry.

- Documented ER/PgR status.

- Prior hormone therapy for metastatic disease is allowed but must stop before study entry.

- KPS>70.

- Life expectancy of =12 weeks

Exclusion Criteria:

- Previous chemotherapy for metastatic breast cancer.

- Prior adjuvant/neoadjuvant chemotherapy within 6 months prior to first study treatment administration.

- Prior (radical)radiotherapy for the treatment of metastatic disease or major surgical procedure within 28 days prior to the first study treatment,

- Inadequate bone marrow function: absolute neutrophil count (ANC): <1.5 x 109/L, platelet count<75 x 109/L or hemoglobin <100g/L.

- Inadequate liver or renal function, defined as:

1. Serum (total) bilirubin >2 x the upper limit of normal (ULN) for the institution

2. AST/SGOT or ALT/SGPT >2.5 x ULN (>5 x ULN in patients with liver metastases)

3. ALP >2.5 x ULN at baseline (>5 x ULN in patients with liver metastases).

4. Serum creatinine>140umol/L.

- Pregnant or lactating females.

- Her-2 positive (ICH +++ or FISH positive).

- Symptomatic cerebral parenchyma and/or leptomeningeal metastases.

- Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.

- Pre-existing peripheral neuropathy =grade 1 according NCI CTCAE 4.0.

- Mental disease or other conditions affecting on the compliance of patients.

- Other serious disease or medical condition:

1. History of uncontrolled seizures, CNS disorders or psychiatric disability judged by the Investigator to be clinically significant precluding informed consent.

2. Congestive heart failure, or unstable angina, myocardial infarction within =6 months prior to the first study treatment, uncontrolled hypertension and high risk, uncontrolled arrhythmias.

3. Uncontrolled acute infection

- Inability to take or absorption oral medications.

- Concurrent or within 30 days using drugs of other clinical trials.

- Previous treatments containing Capecitabine (whether adjuvant or palliative treatment).

- Previous treatments containing docetaxel within 12 months.

- Known hypersensitivity to any of the study treatments or excipients.

- Any other conditions the research consider not appropriate to take part in the trial.

Study Design


Intervention

Drug:
Docetaxel plus Capecitabine
Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration. For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
Intermittent Capecitabine
Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle
Metronomic Capecitabine
Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle

Locations

Country Name City State
China Cancer Institute and Hospital, Chinese Academy Of Medical Sciences Beijing

Sponsors (2)

Lead Sponsor Collaborator
Binghe Xu Hoffmann-La Roche

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) Time from randomization to progression or death (whichever occurred first). up to 36 months
Secondary Adverse events (AEs) Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0), premature withdrawals and vital signs. Hand-foot syndrome and diarrhea will be specially interested.
Adverse events of special interest: hand-foot syndrome and diarrhea. The estimated HFS rate will be about 60% from intermittent Capecitabine vs about 10% from metronomic Capecitabine, diarrhea rate will be about 50% from intermittent Capecitabine vs about 10% from metronomic Capecitabine.
up to 36 months
Secondary Overall survival (OS): Time from randomization to death up to 52 months
Secondary Overall Response rates (ORR) Defined as CR+PR, assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase. up to 36 months
Secondary Clinical Benefit rate (CBR) Defined as CR+PR+SD, assessed based on on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria. It will be evaluated in the initial treatment phase and the maintenance treatment phase up to 36 months
Secondary Time to Progression (TTP) Time from randomization to disease progression up to 36 months
Secondary QoL Using the EORTC quality of life questionnaire QLQ-C30 up to 36 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Active, not recruiting NCT03664778 - Abbreviated Breast MRI After Cancer Treatment
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Active, not recruiting NCT04568902 - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Phase 1
Completed NCT02860585 - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation N/A
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT03698942 - Delphinus SoftVueâ„¢ ROC Reader Study
Completed NCT00092950 - Exercise in Women at Risk for Breast Cancer Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Not yet recruiting NCT02151071 - The Breast Surgery EnLight and LightPath Imaging System Study Phase 1/Phase 2
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02931552 - Nuevo Amanecer II: Translating a Stress Management Program for Latinas N/A
Recruiting NCT02547545 - Breast Cancer Chemotherapy Risk Prediction Mathematical Model N/A
Completed NCT02303366 - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 Phase 1
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02518477 - Preventive Intervention Against Lymphedema After Breast Cancer Surgery N/A